Download PDF
Semin Liver Dis 2002; 22(4): 339-352
DOI: 10.1055/s-2002-35704
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Autoantibodies and Autoantigens in Autoimmune Hepatitis

Christian P. Strassburg, Michael P. Manns
  • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
Further Information

Publication History

Publication Date:
25 November 2002 (online)

    Permissions and Reprints

ABSTRACT

The diagnosis of autoimmune hepatitis (AIH) relies on the exclusion of viral, metabolic, genetic, and toxic etiologies of chronic hepatitis or hepatic injury. There are few parameters that positively predict the presence of AIH. Autoantibodies have been intensively evaluated in this respect and have led to the classification of AIH into three serological subgroups: antinuclear and smooth muscle antibody-positive (ANA/SMA, type 1), liver-kidney microsomal antibody-positive (LKM-1, type 2), and soluble liver antigen/liver-pancreas antigen antibody-positive (SLA/LP, type 3) AIH. Although there are few clinical implications resulting from this classification, autoantibody profiles indicate that AIH is a heterogenous group of entities. The molecular characterization of B cell autoimmunity has led to the identification of major phase I and phase II metabolic enzymes as well as structural and functional components of the cell nucleus as immunologic targets. Autoantibodies and their corresponding autoantigens are intensively studied to provide clues to the understanding of disease initiation, tissue specificity, and propagation of hepatic autoimmune diseases.

KEYWORDS

Autoantibodies - metabolic enzymes - UGT - CYP - LKM - SLA

REFERENCES

  • 1 Waldenström J. Leber, Blutproteine und Nahrungseiweisse.  Dtsch Gesellsch Verd Stoffw . 1950;  15 113-119
    PubMedGoogle Scholar
  • 2 Manns M P, Strassburg C P, Obermayer-Straub P. Autoimmune hepatitis. In: Theofilopoulos AN, Bona CA, eds. The Molecules Pathology of Autoimmune Diseases, 2nd ed New York: Marcel Dekker 2000: 915-950
    Google Scholar
  • 3 Manns M P, Paumgartner G, Leuschner U. Immunology and Liver Boston, MA: Kluwer 2000
  • 4 Strassburg C P, Obermayer-Straub P, Manns M P. Autoimmunity in liver diseases.  Clin Rev Allergy Immunol . 2000;  18 127-139
    PubMedGoogle Scholar
  • 5 Mackay I R, Taft L I, Cowling D C. Lupoid hepatitis.  Lancet . 1956;  2 1323-1326
    PubMedGoogle Scholar
  • 6 Mackay I R. Immunological aspects of chronic active hepatitis.  Hepatology . 1983;  3 724-728
    PubMedGoogle Scholar
  • 7 Manns M P, Strassburg C P. Autoimmune hepatitis: clinical challenges.  Gastroenterology . 2001;  120 1502-17
    CrossrefPubMedGoogle Scholar
  • 8 Czaja A J, Manns M P. The validity and importance of subtypes in autoimmune hepatitis: a point of view.  Am J Gastroenterol . 1995;  90 1206-1211
    PubMedGoogle Scholar
  • 9 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type 2.  Proc Natl Acad Sci USA . 1988;  85 8256-8260
    PubMedGoogle Scholar
  • 10 Guenguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver-kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily.  J Exp Med . 1988;  168 801
    CrossrefPubMedGoogle Scholar
  • 11 Homberg J C, Abuaf N, Bernard O. Chronic active hepatitis associated with anti liver/kidney microsome type 1: a second type of ``autoimmune'' hepatitis.  Hepatology . 1987;  7 1333-1339
    PubMedGoogle Scholar
  • 12 Manns M, Meyer zum Büschenfelde K H, Slusarczyk J, Dienes H P. Detection of liver-kidney microsomal autoantibodies by radioimmunoassay and their relation to antimitochondrial antibodies in inflammatory liver disease.  Clin Exp Immunol . 1984;  54 600-608
    PubMedGoogle Scholar
  • 13 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal antibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.  J Clin Invest . 1989;  83 1066-1072
    PubMedGoogle Scholar
  • 14 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K H. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.  Lancet . 1987;  I 292-294
    PubMedGoogle Scholar
  • 15 Berg P A, Stechemesser E, Strienz J. Hypergammaglobulinaemische chronisch aktive Hepatitis mit Nachweis von Leber-Pankreas-spezifischen komplementbindenden Antikörpern.  Verh Dtsch Ges Inn Med . 1981;  87 821-827
    PubMedGoogle Scholar
  • 16 Stechemesser E, Klein R, Berg P A. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis.  Hepatology . 1993;  18 1-9
    CrossrefPubMedGoogle Scholar
  • 17 Costa M, Rodriguez-Sanchez J L, Czaja A J, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis.  Clin Exp Immunol . 2000;  121 364-374
    CrossrefPubMedGoogle Scholar
  • 18 Gelpi C, Sontheimer E, Rodriguez-Sanchez J. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion.  Proc Natl Acad Sci USA . 1992;  89 9739-9743
    PubMedGoogle Scholar
  • 19 Wies I, Brunner S, Henninger J. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.  Lancet . 2000;  355 1510-1515
    CrossrefPubMedGoogle Scholar
  • 20 Volkmann M, Martin L, Bäurle A. Soluble liver antigen: isolation of a 35 kD recombinant protein (SLA-P35) specifically recognizing sera from patients with autoimmune hepatitis type 3.  Hepatology . 2001;  33 591-596
    CrossrefPubMedGoogle Scholar
  • 21 Kanzler S, Weidemann C, Gerken G. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.  J Hepatol . 1999;  31 635-640
    CrossrefPubMedGoogle Scholar
  • 22 Obermayer-Straub P, Strassburg C P, Manns M P. Autoimmune hepatitis.  J Hepatol . 2000;  32 181-197
    PubMedGoogle Scholar
  • 23 Obermayer-Straub P, Perheentupa J, Braun S. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.  Gastroenterology . 2001;  121 668-677
    PubMedGoogle Scholar
  • 24 Clemente M G, Obermayer-Straub P, Meloni A. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1.  J Clin Endocrinol Metabol . 1997;  82 1353-1361
    CrossrefPubMedGoogle Scholar
  • 25 Clemente M G, Meloni A, Obermayer-Straub P. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1.  Gastroenterology . 1998;  114 324-328
    PubMedGoogle Scholar
  • 26 Obermayer-Straub P, Strassburg C P, Manns M P. Autoimmune polyglandular syndrome type 1.  Clin Rev Allergy Immunol . 2000;  18 167-183
    PubMedGoogle Scholar
  • 27 Aaltonen J, Börses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21.  Nature Genet . 1994;  8 83-87
    CrossrefPubMedGoogle Scholar
  • 28 Rinderle C, Christensen H M, Schweiger S, Lehrach H, Yaspo M L. AIRE encodes a nuclear protein co-localizing with cytoskeletal filaments: altered sub-cellular distribution of mutants lacking the PHD zinc fingers.  Hum Mol Genet . 1999;  8 277-290
    CrossrefPubMedGoogle Scholar
  • 29 Vogel A, Liermann H, Harms A. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1.  Hepatology . 2001;  33 1047-1052
    CrossrefPubMedGoogle Scholar
  • 30 Alvarez F, Berg P A, Bianchi F B. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol . 1999;  31 929-938
    CrossrefPubMedGoogle Scholar
  • 31 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology . 1993;  18 998-1005
    CrossrefPubMedGoogle Scholar
  • 32 Strassburg C P, Manns M P. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease.  J Hepatol . 1999;  31 751
    CrossrefPubMedGoogle Scholar
  • 33 Strassburg C, Alex B, Zindy F. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic diseases.  J Hepatol . 1996;  25 859-866
    CrossrefPubMedGoogle Scholar
  • 34 Tan M T. Autoantibodies in pathology and cell biology.  Cell . 1991;  67 841-842
    CrossrefPubMedGoogle Scholar
  • 35 Czaja A J, Nishioka M, Morhed S A, Haciya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis.  Gastroenterology . 1994;  107 200-207
    PubMedGoogle Scholar
  • 36 Czaja A J, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis.  J Hepatol . 1995;  23 32-38
    CrossrefPubMedGoogle Scholar
  • 37 Czaja A J, Cassani F, Cataleta M, Valenti P, Bianchi F B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.  Hepatology . 1996;  24 1068-1073
    CrossrefPubMedGoogle Scholar
  • 38 Toh B H. Smooth muscles autoantibodies and autoantigens.  Clin Exp Immunol . 1979;  38 621-628
    PubMedGoogle Scholar
  • 39 Manns M P, Obermayer-Straub P, Lüttig B. Autoimmune diseases: the liver. In: Rose NR, Mackay IR, eds. Part 2: Organs and Tissues, 3rd ed San Diego, CA: Academic Press 1998: 511-544
    Google Scholar
  • 40 Tan E M, Chan E KL, Sullivan K F, Rubin R L. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity.  Clin Immunol Immunopathol . 1988;  47 121-141
    CrossrefPubMedGoogle Scholar
  • 41 Lassoued K, Brenard R, Degos F. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis.  Gastroenterology . 1990;  99 181-186
    PubMedGoogle Scholar
  • 42 Nickowitz R E, Wozniak R W, Schaffner F, Worman H J. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis.  Gastroenterology . 1994;  106 193-199
    PubMedGoogle Scholar
  • 43 Bandin O, Courvalin J C, Poupon R. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis.  Hepatology . 1996;  23 1020-1024
    CrossrefPubMedGoogle Scholar
  • 44 Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis.  Gastroenterology . 1996;  110 840-847
    PubMedGoogle Scholar
  • 45 Szostecki C, Krippner H, Penner E, Bautz F A. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100).  Clin Exp Immunol . 1987;  68 108-116
    PubMedGoogle Scholar
  • 46 Lin F, Noyer C M, Ye Q, Courvalin J C, Worman H J. Autoantibodies from patients with primary biliary cirrhosis recognize a region within the nucleoplasmic domain of inner nuclear membrane protein LBR.  Hepatology . 1996;  23 57-61
    PubMedGoogle Scholar
  • 47 Sternsdorf T, Guldner H H, Szostecki C, Grotzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis.  Scand J Immunol . 1995;  42 257-268
    PubMedGoogle Scholar
  • 48 Czaja A J. Frequency and nature of the variant syndromes of autoimmune liver disease.  Hepatology . 1998;  28 360-365
    CrossrefPubMedGoogle Scholar
  • 49 Manns M P, Krüger M. Genetics in liver diseases.  Gastroenterology . 1994;  106 1676-1697
    PubMedGoogle Scholar
  • 50 Ben-Ari Z, Dhillon A P, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis.  Hepatology . 1993;  18 10-15
    CrossrefPubMedGoogle Scholar
  • 51 Michieletti P, Wanless I R, Katz A. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.  Gut . 1994;  35 260-265
    PubMedGoogle Scholar
  • 52 Colombato L A, Alvarez F, Cote J, Huet P M. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?.  Gastroenterology . 1994;  107 1839-1843
    PubMedGoogle Scholar
  • 53 Obermayer-Straub P, Strassburg C P, Manns M P. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases.  Can J Gastroenterol . 2000;  14 429-439
    PubMedGoogle Scholar
  • 54 Tukey R H, Johnson E F. Molecular aspects of drug-metabolizing enzymes. In: Pratt W, Taylor P, eds. Principles of Drug Action New York: Churchill Livingston 1990: 423-468
    Google Scholar
  • 55 Tukey R H, Strassburg C P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease.  Annu Rev Pharmacol Toxicol . 2000;  40 581-616
    CrossrefPubMedGoogle Scholar
  • 56 Tukey R H, Strassburg C P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract.  Mol Pharmacol . 2001;  59 405-414
    PubMedGoogle Scholar
  • 57 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders.  Clin Exp Immunol . 1973;  15 331-344
    PubMedGoogle Scholar
  • 58 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest . 1991;  88 1370-1378
    PubMedGoogle Scholar
  • 59 Manns M, Zanger U, Gerken G. Patients with type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM1 autoantibodies in vitro but not in vivo.  Hepatology . 1990;  12 127-132
    PubMedGoogle Scholar
  • 60 Löhr H F, Schlaak J F, Lohse A W. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis.  Hepatology . 1996;  24 1416-1421
    PubMedGoogle Scholar
  • 61 Duclos-Vallee J C, Hajoui O, Yamamoto A M, Jacqz-Aigrin E, Alvarez F. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies.  Gastroenterology . 1995;  108 470-476
    PubMedGoogle Scholar
  • 62 Dalekos G N, Wedemeyer H, Obermayer-Straub P. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during a-interferon treatment.  J Hepatol . 1999;  30 366-375
    CrossrefPubMedGoogle Scholar
  • 63 Ma Y, Peakman M, Lobo-Yeo A. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.  Clin Exp Immunol . 1994;  97 94-99
    PubMedGoogle Scholar
  • 64 Yamamoto A M, Cresteil D, Boniface O, Clerc F F, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1).  Eur J Immunol . 1993;  23 1105-1111
    PubMedGoogle Scholar
  • 65 Muratori L, Parola M, Ripalti A. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.  Gut . 2000;  46 553-561
    CrossrefPubMedGoogle Scholar
  • 66 Loeper J, Descartoire V, Maurice M. Cytochromes P450 in human hepatocyte plasma membrane: recognition by several autoantibodies.  Gastroenterology . 1993;  104 203-216
    PubMedGoogle Scholar
  • 67 Trautwein C, Ramadori G, Gerken G, Meyer zum Büschenfelde K H, Manns M P. Regulation of cytochrome P450 2D by acute phase mediators in C3H/HeJ mice.  Biochem Biophys Res Comm . 1992;  182 617-623
    CrossrefPubMedGoogle Scholar
  • 68 Zimmerman H J, Lewis J H, Ishak K G, Maddrey W. Ticrynafen-associated hepatic injury: analysis of 340 cases.  Hepatology . 1984;  4 315-323
    CrossrefPubMedGoogle Scholar
  • 69 Beaune P H, Pessayre D, Dansette P, Mansuy D, Manns M P. Autoantibodies against cytochromes P450: role in human diseases.  Adv Pharmacol . 1994;  30 199-245
    PubMedGoogle Scholar
  • 70 Homberg J C, Abuaf N, Helmy-Khalil S. Drug induced hepatitis associated with anticytoplasmic organelle autoantibodies.  Hepatology . 1985;  5 722-725
    PubMedGoogle Scholar
  • 71 Manns M P, Griffin K J, Quattrochi L. Identification of cytochrome P450 IA2 as a human autoantigen.  Arch Biochem Biophys . 1990;  280 229-232
    CrossrefPubMedGoogle Scholar
  • 72 Strassburg C P, Obermayer-Straub P, Manns M P. Autoimmunity in hepatitis C and D virus infection.  J Viral Hepat . 1996;  3 49-59
    PubMedGoogle Scholar
  • 73 Gebre-Medhin G, Husebye E S, Gustafsson J. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I.  FEBS Lett . 1997;  412 439-445
    CrossrefPubMedGoogle Scholar
  • 74 Dalekos G N, Obermayer-Straub P, Maeda T, Tsianos E V, Manns M P. Antibodies against cytochrome P4502A6 (CYP2A6) in patients with chronic viral hepatitis are mainly linked to hepatitis C virus infection.  Digestion . 1998;  59 S36
    CrossrefPubMedGoogle Scholar
  • 75 Bourdi M, Larrey D, Nataf J. Anti-liver endoplasmic reticulum antibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine hepatitis.  J Clin Invest . 1990;  85 1967-1973
    CrossrefPubMedGoogle Scholar
  • 76 Sacher M, Blümel P, Thaler H, Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies.  J Hepatol . 1990;  10 364-369
    PubMedGoogle Scholar
  • 77 Bourdi M, Gautier J C, Mircheva J. Anti-liver microsomes autoantibodies and dihydralazine induced hepatitis: Specificity of autoantibodies and inductive capacity of the drug.  Mol Pharmacol . 1992;  42 280-285
    PubMedGoogle Scholar
  • 78 Van Pelt F, Straub P, Manns M. Molecular basis of drug-induced immunological liver injury.  Semin Liver Dis . 1995;  15 283-300
    PubMedGoogle Scholar
  • 79 Crivelli O, Lavarini C, Chiaberge E. Microsomal autoantibodies in chronic infection with HBsAg associated delta (delta) agent.  Clin Exp Immunol . 1983;  54 232-238
    PubMedGoogle Scholar
  • 80 Philipp T, Durazzo M, Trautwein C. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D.  Lancet . 1994;  344 578-581
    CrossrefPubMedGoogle Scholar
  • 81 Strassburg C, Obermayer-Straub P, Alex B. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis.  Gastroenterology . 1996;  11 1582-1592
    PubMedGoogle Scholar
  • 82 Strassburg C P, Manns M P, Tukey R H. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGTIA8.  J Biol Chem . 1998;  273 8719-8726
    CrossrefPubMedGoogle Scholar
  • 83 Kenna J G, Neuberger J M. Immunopathology and treatment of halothane hepatitis.  Clin Immunother . 1995;  3 108-124
    PubMedGoogle Scholar
  • 84 Kenna J G. Immunoallergic drug-induced hepatitis: lessons from halothane.  J Hepatol . 1997;  26 5-12
    PubMedGoogle Scholar
  • 85 Pohl L R, Pumford N R, Martin J L. Mechanisms, chemical structures and drug metabolism.  Eur J Haematol . 1996;  57 98-104
    PubMedGoogle Scholar
  • 86 Pessayre D. Toxic and immune mechanisms leading to acute and subacute drug induced liver injury. In: Miguet JP, Dhumeaux D, eds. Progress in Hepatology Paris: John Libbey Eurotext 1993: 23-39
    Google Scholar
  • 87 Beaune P, Dansette P M, Mansuy D. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug.  Proc Natl Acad Sci USA . 1987;  84 551-555
    CrossrefPubMedGoogle Scholar
  • 88 Eliasson E, Kenna G. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.  Mol Pharmacol . 1996;  50 573-582
    PubMedGoogle Scholar
  • 89 Leeder J S, Riley R J, Cook V A, Spielberg S P. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions.  J Pharmacol Exp Ther . 1992;  263 360-367
    PubMedGoogle Scholar
  • 90 Albano E, Clot P, Morimoto M. Role of cytochrome P450 2E1-dependent formation if hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol.  Hepatology . 1996;  23 155-163
    PubMedGoogle Scholar
  • 91 Clot P, Albano E, Eliasson E. Cytochrome P450 2E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics.  Gastroenterology . 1996;  111 206-216
    PubMedGoogle Scholar
  • 92 Durazzo M, Philipp T, Van Pelt F A M N. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection.  Gastroenterology . 1995;  108 455-462
    PubMedGoogle Scholar
  • 93 Czaja A J, Manns M P, Homburger H A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.  Gastroenterology . 1992;  103 1290-1295
    PubMedGoogle Scholar
  • 94 Manns M P, Jentzsch M, Mergener K. Discordant manifestation of LKM-1 antibody positive autoimmune hepatitis in identical twins.  Hepatology . 1990;  12 840
    PubMedGoogle Scholar
  • 95 Agnello V, Chung R T, Kaplan L. A role of hepatitis C virus infection in type II cryoglobulinemia.  N Engl J Med . 1992;  19 1490
    PubMedGoogle Scholar
  • 96 Cacoub P, Lunel-Fabiani F, Huong Du T L. Polyarteritis nodosa and hepatitis C infection.  Ann Intern Med . 1992;  116 605-606
    PubMedGoogle Scholar
  • 97 Haddad J, Deny P, Munz-Gotheil C. Lymphocytic sialadenitis of Sjörgen's syndrome associated with chronic hepatitis c virus liver disease.  Lancet . 1992;  339 321-323
    CrossrefPubMedGoogle Scholar
  • 98 Johnson R J, Gretch D R, Yamabe C. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.  N Engl J Med . 1993;  18 465-470
    PubMedGoogle Scholar
  • 99 Michel G, Ritter A, Gerken G. Anti-GOR and hepatitis C virus in autoimmune liver diseases.  Lancet . 1992;  339 267-269
    CrossrefPubMedGoogle Scholar
  • 100 Yamamoto A M, Cresteil D, Homberg J C, Alvarez F. Characterization of anti-liver-kidney microsome antobody (anti-LKM1) from hepatitis C virus-positive and -negative sera.  Gastroenterology . 1993;  104 1762-1767
    PubMedGoogle Scholar
  • 101 Muratori L, Lenzi M, Ma Y. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.  Gut . 1995;  37 406-412
    PubMedGoogle Scholar
  • 102 Yamamoto A M, Johanet C, Duclos-Vallee J C. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.  Clin Exp Immunol . 1997;  108 396-400
    CrossrefPubMedGoogle Scholar
  • 103 Todros L, Touscoz G, D'Urso N. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders.  J Hepatol . 1991;  13 128-131
    PubMedGoogle Scholar
  • 104 Muratori L, Lenzi M, Cataleta M, Giostra F, Ballardini G. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.  J Hepatol . 1994;  21 199-203
    CrossrefPubMedGoogle Scholar
  • 105 Strassburg C P, Manns M P. Jaundice, genes and promoters.  J Hepatol . 2000;  33 476-479
    CrossrefPubMedGoogle Scholar
  • 106 Strassburg C P, Vogel A, Kneip S, Tukey R H, Manns M P. Polymorphisms of the UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer.  Gut . 2002;  50 851-856
    CrossrefPubMedGoogle Scholar
  • 107 Vogel A, Kneip S, Barut S. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGTIA7 gene.  Gastroenterology . 2001;  121 1136-1144
    PubMedGoogle Scholar
  • 108 Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.  N Engl J Med . 1990;  322 1829-1836
    CrossrefPubMedGoogle Scholar
  • 109 Betterle C, Greggio N A, Volpato M. Autoimmune polyglandular syndrome type 1.  J Clin Endocrinol Metab . 1998;  83 1049-1055
    PubMedGoogle Scholar
  • 110 Nagamine K, Peterson P, Scott H S. Positional cloning of the APECED gene.  Nature Genet . 1997;  17 393-398
    CrossrefPubMedGoogle Scholar
  • 111 Baeres M, Herkel J, Czaja A J. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.  Gut . 2002;  51 259-264
    CrossrefPubMedGoogle Scholar
  • 112 Ma Y, Okamoto M, Thomas M G. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology . 2002;  35 658-664
    CrossrefPubMedGoogle Scholar
  • 113 Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.  Am J Gastroenterol . 2002;  97 413-419
    CrossrefPubMedGoogle Scholar
  • 114 Poralla T, Treichel U, Löhr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases.  Semin Liver Dis . 1991;  11 215-222
    PubMedGoogle Scholar
  • 115 Treichel U, Gerken G, Rossol S. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis.  J Hepatol . 1993;  19 55-63
    CrossrefPubMedGoogle Scholar
  • 116 Lenzi M, Manotti P, Muratori L. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection.  Gut . 1995;  36 749-754
    PubMedGoogle Scholar
  • 117 Martini E, Abuaf N, Cavalli F. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.  Hepatology . 1988;  8 1662-1666
    PubMedGoogle Scholar
  • 118 Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Fomiminotransferase cyclodeaminase is an organ specific autoantigen recognized by sera of patients with autoimmune hepatitis.  Gastroenterology . 1999;  116 643-649
    PubMedGoogle Scholar
  • 119 Mulder A HL, Horst G, Haagsma E B. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases.  Hepatology . 1993;  17 411-417
    CrossrefPubMedGoogle Scholar
  • 120 Targan S R, Landers C, Vidrich A, Czaja A J. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis.  Gastroenterology . 1995;  108 1159-1166
    PubMedGoogle Scholar